Profiles of Patients' Blood May Indicate Course of Multiple Sclerosis | GenomeWeb

Some patients with multiple sclerosis have a relatively benign course of disease while others experience a more severe disease. "We can't tell the difference when they first present to us," says Philip De Jager, an associate professor at Harvard Medical School. "Clinically, it is impossible to say what course a patient will take. Similarly also for the drugs that we have, they work to some extent, but we can't predict who is going to respond to a given drug."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.